Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) have received a consensus rating of “Hold” from the seven research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $8.50.

A number of research analysts have recently issued reports on the stock. Jefferies Group LLC set a $5.00 price objective on shares of Mirati Therapeutics and gave the company a “hold” rating in a report on Friday, August 4th. ValuEngine upgraded shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Finally, Zacks Investment Research cut shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 4th.

A number of hedge funds have recently bought and sold shares of the company. KCG Holdings Inc. purchased a new stake in Mirati Therapeutics during the first quarter worth $106,000. Trexquant Investment LP raised its stake in Mirati Therapeutics by 62.2% in the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16,447 shares during the period. Susquehanna International Group LLP raised its stake in Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after buying an additional 16,030 shares during the period. PDT Partners LLC purchased a new stake in Mirati Therapeutics during the second quarter worth $200,000. Finally, Bank of New York Mellon Corp raised its stake in Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after buying an additional 11,753 shares during the period. 60.17% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/mirati-therapeutics-inc-mrtx-receives-average-rating-of-hold-from-analysts/1529706.html.

Shares of Mirati Therapeutics (NASDAQ MRTX) traded up 3.70% during mid-day trading on Tuesday, hitting $5.60. The stock had a trading volume of 11,058 shares. The stock’s 50-day moving average price is $4.72 and its 200-day moving average price is $4.52. The stock’s market capitalization is $139.83 million. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $7.22.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.